Insulet had five patents in artificial intelligence during Q1 2024.The patents filed by Insulet Corp in Q1 2024 focus on enhancing safety and accuracy in medicament delivery devices. They include features such as identifying duplicate boluses, setting limits on doses, automatic meal detection, delivery of partial boluses based on glucose levels, and resolving conflicts among multiple devices. Additionally, the patents also cover a system for detecting and handling occlusions in the fluid path, as well as a method for determining the risk of hypoglycemic or hyperglycemic conditions based on various factors and providing alerts to the user. GlobalData’s report on Insulet gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Insulet Corp - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

Insulet had no grants in artificial intelligence as a theme in Q1 2024.

Recent Patents

Application: Safety and accuracy measures for medicament bolus delivery (Patent ID: US20240075214A1)

The patent filed by Insulet Corp. describes a medicament delivery device that incorporates safety and accuracy measures to prevent the inadvertent delivery of duplicate medicament boluses. The device sets limits for maximum allowable medicament bolus doses and maximum cumulative bolus doses over an interval. It also features automatic meal detection to adjust or reject user-requested medicament bolus doses based on meal detection and glucose level trends. Additionally, the device allows for the delivery of partial boluses and the delivery of remainders of boluses based on acceptable glucose level trends. The patent also addresses potential conflicts among multiple medicament delivery devices by providing a single actor, such as a medicament delivery controller, with sole control over dosing and delivery.

The claims of the patent detail methods performed by a processor of an insulin delivery device, including monitoring glucose levels, adjusting insulin bolus doses based on glucose level trends, and delivering adjusted bolus doses to the user. The device can determine if the user has eaten within an interval or received a bolus of insulin recently, adjusting the specified bolus dose accordingly. The patent also covers the use of external electronic devices for insulin delivery requests, analyzing glucose level trends to identify meal ingestion, and utilizing machine learning models for analysis. The insulin delivery system described in the patent includes a reservoir storing insulin, a bolus calculator, a controller for automated delivery, and a user interface for communication, with the option for the user interface to be on a remote device such as a smartphone or smartwatch.

To know more about GlobalData’s detailed insights on Insulet, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.